All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes

All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes

Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA1C and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia. Patients with uncontrolled diabetes might be treated by the complementary action of insulin plus DPP-4 inhibitors. Here, we...

Full description

Bibliographic Details
Main Authors: Fu-Shun Yen, Jen-Huai Chiang, Chii-Min Hwu, Yu-Hsin Yen, Boniface J. Lin, James Cheng-Chung Wei, Chih-Cheng Hsu
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Endocrine Disorders
Subjects:
All-cause mortality
Cohort study
Match
Online Access:http://link.springer.com/article/10.1186/s12902-018-0330-7

Internet

http://link.springer.com/article/10.1186/s12902-018-0330-7

Similar Items